Clinical Trials Logo

Clinical Trial Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.


Clinical Trial Description

The investigators primarily aim to observe the time to first relapse from initiation of baricitinib treatment. The secondary outcomes are to determine: The safety profile of baricitinib in participants with NMO and whether baricitinib improves Expanded Disability Status Scale (EDSS), et al. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05792462
Study type Interventional
Source Tianjin Medical University General Hospital
Contact Qiang Liu, M.D.,Ph.D.
Phone +86 15022439149
Email qliu@tmu.edu.cn
Status Recruiting
Phase Phase 1/Phase 2
Start date April 15, 2023
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05154734 - Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Phase 1/Phase 2
Withdrawn NCT03829566 - Autologous Transplant To End NMO Spectrum Disorder Phase 2/Phase 3
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT05432713 - A Study of LP-168 in Healthy Volunteers Phase 1
Not yet recruiting NCT04822623 - Imaging Evaluation of Central Nervous Autoimmune Diseases
Completed NCT04227470 - A Study of HBM9161 in NMOSD Patients Phase 1
Not yet recruiting NCT06280755 - Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Recruiting NCT05414890 - Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Recruiting NCT05840055 - ACT With NMOSD Patients and Caregivers Pilot Study N/A
Recruiting NCT05004493 - Biorepository and Registry for Plasma Exchange Patients
Completed NCT05896605 - Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder Phase 4
Recruiting NCT04106830 - Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
Completed NCT03766347 - Pediatric NMOSD Observational Study
Recruiting NCT05154370 - China National Registry of Neuro-Inflammatory Diseases
Recruiting NCT06443333 - National, Multicentric Registry Study on Neuroimmunological Diseases in China
Recruiting NCT05145361 - Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) Early Phase 1
Not yet recruiting NCT05974293 - A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Phase 2
Completed NCT04355611 - Epidemiological Characteristics of COVID-19 in Patients With MS or NMO